Table 1.

Comparison of IRIN chemo plus anti‐PD‐1/anti‐PD‐L1 combination in the literature and this study

Ref.	Treatments	Cancer model	Anticancer effect	Key immunological and other biological findings of IRIN
[ 45a ]	Free IRIN w/wo a‐PD‐L1	Subcutaneous FM3A Breast Cancer	Potency ranking: Free IRIN + a‐PD‐L1 > Free IRIN ≈ a‐PD‐L1 > saline	CD8/Treg ratio ↑ MHC class I ↑ PD‐L1 ↑
[ 45b ]	Liposomal IRIN (Onivyde/MM398) w/wo a‐PD‐1/a‐PD‐L1	SubcutaneousMC38/gp100 Colon Cancer	Potency ranking: Liposomal IRIN + a‐PD‐1/ a‐PD‐L1 > liposomal IRIN a‐PD‐1/ a‐PD‐L1 alone ≈ saline	CD8/Treg ratio ↑ Granzyme B+ T cells ↑
This study	Free IRIN w/wo a‐PD‐1 ONIVYDE w/wo a‐PD‐1 IRIN silicasome w/wo a‐PD‐1	Orthotopic KPC Pancreatic Cancer	Potency ranking: IRIN silicasome + a‐PD‐1 > IRIN silicasome ≈ IRIN + a‐PD‐1 > free IRIN ≈ a‐PD‐1 ≈ saline IRIN silicasome + a‐PD‐1 > IRIN silicasome ≈ ONIVYDE + a‐PD‐1 > ONIVYDE > a‐PD‐1 ≈ saline [Note: “IRIN silicasome + a‐PD‐1” exhibited the longest survival outcome]	CD8/Treg ratio ↑ PD‐L1 expression ↑ Granzyme B+ T cells ↑ Perforin+ T cells ↑ IFN‐γ production ↑ ICD (CRT, HMGB1) and ER stress ↑ Enrichment in acidic vesicles and autophagy inhibition ↑